// App-Quantinova.ai

OT1-08-02 : TRYbeCA-2: A randomized phase 2/3 study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer (NCT03674242)

Researchers

Presenter

  • Ahmad Awada

Principal Investigators

  • Javier Cortes

  • Sarah Slater

  • Iain MacPherson

  • Tibor Csoszi

  • Jean-Baptiste Bertrand

  • Anne-Sophie Clermont

  • Rachel Pollard

  • Romain Chrestia-Blanchine

  • Nigel Biswas-Baldwin

  • Hagop Youssoufian

  • Iman El-Hariry

Medical Centers

  • Institute Jules Bordet, Brussels, Belgium

  • Hospital Ruber Internacional Madrid Spain

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Jasz-Nagykun Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary

  • Erytech, Lyon, France

  • Erytech, Boston, MA

Locations

  • Belgium

  • Spain

  • United Kingdom

  • Hungary

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • ERY001

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multinational

Phase

  • II/III

Study Id's

  • NCT03674242

  • NCT02195180

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved